Glenn Tracey, CEO of Microsaic, commented, “Traditional mass spectrometers are large, expensive, and require operation by specialists in centralised laboratories. Integrated real-time MS, decentralized and at the point-of-need, could provide

Glenn Tracey, CEO of Microsaic, commented, “Bringing the power of the centralised laboratory to in-situ bioprocessing line measurements, the Microsaic MiD® ProteinID reduces key bioprocessing analyses from days to minutes.

Optimize productivity Designed to bring real-time mass detection to laboratories and processing facilities, Microsaic’s chip-based, miniaturized MS technology allows agile sample detection and identification at the point of use. Providing access to more detailed

Richard Moseley, Chief Technologist at Microsaic talks to Biopharma International about process analytical technology (PAT) for monitoring and controlling biopharma production processes. When FDA’s process analytical technology (PAT) initiative was

Microsaic Systems’ Chief Technologist, Richard Moseley, explains the need for miniaturised mass spectrometry, and where the technology can take some key industries such as pharma and biopharma. Arguably the work-horse

Encouraging efficiency in pharmaceutical discovery and manufacturing, Microsaic’s Chief Technologist Dr. Richard Moseley discusses chip-based technologies and miniaturisation of mass spectrometry. The current challenges faced by the pharmaceutical industry are

Richard Moseley, Chief Technologist at Microsaic Sytems PLC explains why accurate, timely and efficient measurement techniques are key to optimising production processes in pharmaceutical manufacturing and providing regulators with assurance on

Glenn Tracey, CEO of Microsaic, commented, “I am extremely pleased to partner with iChrom to distribute our compact, point of need MS technology, alongside their impressive technology portfolio. The team